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Respiratory viral infections are a significant burden to
healthcare worldwide. Many whole genome expres-
sion profiles have identified different respiratory viral
infection signatures, but these have not translated to
clinical practice. Here, we performed two integrated,
multi-cohort analyses of publicly available transcrip-
tional data of viral infections. First, we identified a
common host signature across different respiratory
viral infections that could distinguish (1) individuals
with viral infections from healthy controls and from
those with bacterial infections, and (2) symptomatic
from asymptomatic subjects prior to symptom onset
in challenge studies. Second, we identified an influ-
enza-specific host response signature that (1) could
distinguish influenza-infected samples from those
with bacterial and other respiratory viral infections,
(2) was a diagnostic and prognostic marker in influ-
enza-pneumonia patients and influenza challenge
studies, and (3) was predictive of response to influ-
enza vaccine. Our results have applications in the
diagnosis, prognosis, and identification of drug tar-
gets in viral infections.
INTRODUCTION
Respiratory viruses such as influenza and SARS pose a major
threat to global health, yet antiviral drugs have been difficult to
develop. In addition, treating potential pandemic viral strains is
problematic because of the many unknowns about the patho-
genesis of infection. Current anti-viral drugs, which target a path-
ogen’s enzymatic functions and provide a ‘‘one-bug-one-drug’’
approach, use resources inefficiently and are often limited by
the emergence of viral resistance (Locarnini and Warner, 2007;
Richman et al., 2004). The drug-development process requires
the ability to identify specific host factors that are necessary
for viral growth and virulence that could also be potential drug
targets. In light of the large unmet need for novel antiviral strate-
gies, an efficient solution would be to repurpose currentlyImmapproved drugs as broad-spectrum, host-centered antivirals
that could impair viral transmission and prevent clinical pathol-
ogy by identifying host factors that are targeted by existing drugs
and are required for viral growth.
The prevailing approach for studying gene expression profiles
is limited in its ability to identify thesewould-be targets for broad-
spectrum antiviral therapeutics. Many gene expression microar-
ray studies have proposed distinct gene signatures to discrimi-
nate different viral infections (Zaas et al., 2009) or influenza
from bacterial infections (Parnell et al., 2012, 2011; Ramilo
et al., 2007). However, these experiments aim to reduce the ef-
fect of various biological and technical confounding factors as
much as possible by focusing on only one viral infection in one
tissue and using one type of microarray. This standard, single-
cohort approach increases the risk of confounding factors on
gene expression profiles from the specific tissue, technologies,
demographics, and inclusion criteria of the respective studies
or by other unknown biological and technical factors (Parnell
et al., 2011, 2012; Ramilo et al., 2007), all of which can mask
the broad pathways used by multiple viruses to establish
infection.
We have developed an integrated, multi-cohort analysis
framework that leverages the heterogeneity present in public
data repositories (e.g., GEO and ArrayExpress), which in turn in-
creases sample size and allows for the identification and valida-
tion of robust and reproducible signatures of a disease pheno-
type. We have demonstrated the utility of this framework in
identifying novel drug targets, diagnostic biomarkers, and repur-
posing FDA-approved drugs (Chen et al., 2014; Khatri et al.,
2013; Li et al., 2015; Mazur et al., 2014; Sweeney et al., 2015).
We applied our method for two different hypotheses. First, to
obtain a common transcriptional signature across all respiratory
viral infections, we applied our method to three gene expression
datasets of 205 human blood samples from three viral infections
(influenza, human rhinovirus [HRV], and respiratory syncytial vi-
rus [RSV]), measured on two different microarray platforms in
three countries to identify a robust 396-gene meta-virus signa-
ture (MVS) of respiratory viral infections. We tested this signature
against 14 independent cohorts composed of 1,087 blood sam-
ples to show that it was not confounded by sample tissue, treat-
ment, viral strain, or microarray technology.
We performed a separate multi-cohort analysis of influenza
infection studies to illustrate that there were virus-specificunity 43, 1199–1211, December 15, 2015 ª2015 Elsevier Inc. 1199
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Figure 1. Discovery and Validation of Meta
Virus Signature
Effect size heatmaps of 396-gene MVS in 5 dis-
covery (A) and 10 validation (B) cohorts. Each
column is a gene and row is a cohort. The first row
in both heatmaps displays summary effect size for
each gene in discovery or validation cohorts.
Genes are sorted in decreasing order of their
summary effect size in discovery cohorts for both
heatmaps.signatures encompassing smaller subsets of genes. We applied
ourmethod to five influenza gene expression datasets consisting
of 292 samples and identified an 11-gene influenza meta-signa-
ture (IMS). Using 11 additional independent cohorts, we showed
that this influenza-specific signature was able to discriminate (1)
symptomatic from asymptomatic subjects, (2) influenza infection
from other respiratory viral infections, and (3) patients with mixed
influenza and/or bacterial pneumonia from those with bacterial
pneumonia alone. Finally, we bridge the gap between influenza
infection and vaccination by demonstrating that the influ-
enza infection signature is also increased significantly in influ-
enza vaccine responders compared to non-responders.
These two multi-cohort analyses showed that (1) there was a
conserved host response to respiratory viral infections and (2)
there were virus-specific responses that could distinguish
different virus types. Both have significant potential for use in
the diagnosis and treatment of viral infections.
RESULTS
Integrated, Multi-cohort Analysis of Viral Infections
Identifies Broad Anti-virus Responses
We downloaded 18 microarray gene expression datasets from
the NCBI GEO (Barrett et al., 2005) database comprising 2,939
samples obtained from whole blood, PBMCs, or primary epithe-
lial cells (Table S1; Bermejo-Martin et al., 2010; Franco et al.,
2013; Herberg et al., 2013; Hu et al., 2013; Ioannidis et al.,
2012; Li et al., 2011; Loveday et al., 2012;Mejias et al., 2013; Par-
nell et al., 2011, 2012; Ramilo et al., 2007; Reghunathan et al.,
2005; Shapira et al., 2009; Sutejo et al., 2012; Tsang et al.,
2014; Woods et al., 2013; Zaas et al., 2009). These datasets
included healthy controls; individuals with various viral infec-
tions, bacterial infections, or non-infectious systematic inflam-1200 Immunity 43, 1199–1211, December 15, 2015 ª2015 Elsevier Inc.matory response syndrome (SIRS);
individuals that were vaccinated for influ-
enza; and in vitro transfection experi-
ments expressing different viral antigens.
We used five cohorts from three data-
sets, composed of 205 samples for
studying three respiratory viral infections
to identify a potential common viral
response (Table S1; Herberg et al.,
2013; Hu et al., 2013; Ioannidis et al.,
2012). We refer to each study (unique
GSE ID) in GEO as a dataset and a set
of samples for each comparison within a
dataset as a cohort. Unlike a single-cohort experiment, where the goal is to control as many con-
founding factors as possible, we included broad biological and
technical heterogeneity, such as treatment protocols and demo-
graphics, observed in the population by choosing discovery co-
horts that were collected at different centers (with different treat-
ment protocols and demographics) and that profiled more than
one viral infection (influenza, RSV, HRV) across different age
groups (infant and pediatric). We incorporated technical hetero-
geneity in our samples by choosing datasets that were profiled
using microarrays from two different manufacturers and repre-
sented different technological confounding factors (e.g., length
of oligonucleotide probes, sample preparation protocols). In or-
der to avoid the potential influence of a single cohort on the re-
sults due to unequal sample sizes or other unknown confounding
factors among cohorts, we performed a ‘‘leave-one-cohort-out’’
analysis. We hypothesized that the resulting set of genes that
were significantly differentially expressed, irrespective of the
set of cohorts analyzed, would constitute a robust signature of
respiratory viral infection.
We identified 396 differentially expressed genes (161 over-
and 235 underexpressed, p < 3 3 105, FDR < 1%; Figure 1A
and Table S2) during respiratory viral infection, many of which
have been previously identified as differentially expressed after
viral infection such as OASL, TYK2, toll-like receptors (TLRs),
and interferon induced transmembrane proteins (IFITMs) (Par-
nell et al., 2011, 2012; Ramilo et al., 2007; Woods et al.,
2013; Zaas et al., 2009). We refer to the 396-gene set as a
meta-virus signature (MVS). KEGG pathway analysis using
iPathwayGuide (Draghici et al., 2007; Khatri et al., 2008; Tarca
et al., 2009) of the MVS identified 18 significant pathways,
including pathways for viral infections such as Epstein-Barr vi-
rus, influenza A, herpes simplex, and measles (Table S3). Other
significant and relevant KEGG pathways included cell cycle,
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Figure 2. MVS Scores in Four Independent Cohorts of Blood Samples
(A) Comparison of MVS scores in virus-negative, afebrile controls, and patients infected with bacteria or HRV.
(B) Comparison ofMVS scores in healthy controls and patients infectedwith SARS coronavirus. Error bars indicate mean ± SE for a given group of samples.Width
of a violin plot indicates density of samples, where each dot represents a sample.
(C and D) MVS scores in symptomatic and asymptomatic subjects inoculated with influenza (H3N2 in C or H1N1 in D). Smoothed lines indicate loess curves for
symptomatic and asymptomatic subjects. Gray bars indicate 95% confidence intervals for each group.
See also Figure S1.NF-kB signaling, toll-like receptor signaling, lysosome, and
sphingolipid metabolism.
Next, we analyzed the expression of these 396 MVS genes in
10 additional independent cohorts consisting of 329 PBMC or
whole blood samples (226 viral infection samples, 103 controls).
136 out of 161 MVS overexpressed genes (84.5%), and 139 out
of 235 underexpressed MVS genes (59.14%) were statistically
significant (p < 0.05) in the validation cohorts (Figure 1B). These
data indicated that the MVS defined broad immunological re-
sponses in the host to respiratory viral infection.
The MVS Is Specific to Viral Infection
Differential diagnosis of bacterial versus viral infection is
confounded by similar clinical symptoms and underlying condi-
tions such as immunosuppression and extrapulmonary compli-
cations (Babcock et al., 2008; Ison and Lee, 2010; Parnell
et al., 2011, 2012; Ramilo et al., 2007). Therefore, we exploredImmwhether the MVS could distinguish viral infections from bacterial
infections.
First, we examined an independent cohort of children under 3
years of age (GSE: GSE40396) (Hu et al., 2013). For each sample,
we defined an MVS score as the difference between the geo-
metric mean of the 161 overexpressed genes and 235 under-
expressed genes in the MVS. As expected, the MVS scores
in virus-infected children were significantly higher than those in
virus-negative controls (p = 6.88 3 107; receiver operating
characteristic [ROC] area under the curve [AUC] = 1). The MVS
scores were significantly higher in afebrile RSV-infected children
than in those with febrile bacterial infections (p = 6.21 3 104)
and distinguished both groups with high accuracy (ROC
AUC = 0.98) (Figures 2A and S1A). These results suggest that
theMVS score is not confounded by the febrile status of children.
The MVS scores were also higher in another independent
cohort (GSE: GSE1739) (Reghunathan et al., 2005), comprisedunity 43, 1199–1211, December 15, 2015 ª2015 Elsevier Inc. 1201
of patients infected with severe acute respiratory syndrome
(SARS) coronavirus (Figures 2B and S1B). Interestingly, in
GSE40396, the MVS scores were also higher for children with
other viral infections (adenovirus, HHV6, and enterovirus)
compared to virus-negative controls (p = 1.023 108) and those
with bacterial infections (p = 0.012), although none of these infec-
tions were used to define theMVS (Figure S1C). TheMVS scores
also distinguished samples with these viral infections from those
with bacterial infections and samples from healthy controls with
relatively high accuracy (Figure S1D). This indicates that theMVS
might be more broadly applicable than respiratory viruses.
Next, we used an influenza challenge study (GSE: GSE52428),
which inoculated healthy adults with H3N2 or H1N1 to evaluate
changes in the MVS scores over the course of infection (Woods
et al., 2013). The MVS scores remained unchanged over time in
asymptomatic subjects that were not shedding any virus in both
groups. However, the MVS scores increased significantly for vi-
rus-shedding symptomatic subjects over 24–72 hr and began to
decline toward asymptomatic baseline levels as symptoms
resolved (Figures 2C, 2D, S1E, and S1G). Specifically, the MVS
scores for six of the nine H3N2 symptomatic volunteers (67%)
were higher than those of the H3N2 asymptomatic volunteers at
36 hr after inoculation (Figure 2C). Similarly, the MVS scores for
9 of the 12 H1N1 symptomatic volunteers (75%) were higher
than those of the H1N1 asymptomatic volunteers at 53 hr after
inoculation (Figure 2D). The median onset time of symptoms for
H3N2- and H1N1-inoculated volunteers was 49.3 hr (range 24–
84 hr) and 61.3 hr (range 24–108 hr), respectively. Hence, the in-
crease in theMVSscorespreceded respiratory infection symptom
onset inbothstrains anddistinguishedH3N2andH1N1symptom-
atic fromasymptomatic volunteerswith high specificity and sensi-
tivitywithROCAUC forH3N2andH1N1of 0.94 at 36 hr (p = 0.009)
and 0.84 at 53 hr (p = 0.008), respectively (Figures S1F and S1H).
Three H1N1-inoculated subjects (one asymptomatic and two
symptomatic) showedMVS score profiles that were the opposite
of their respective group (Figure S1G). Further examination
of these individuals revealed that the asymptomatic subject,
who followed a trajectory similar to the symptomatic group,
was shedding the virus. The original study referred to this subject
as an ‘‘asymptomatic shedder’’ (Woods et al., 2013). Similarly,
one of the symptomatic subjects, who followed a trajectory
similar to asymptomatic group, was not shedding any virus,
and was therefore referred to as a ‘‘symptomatic non-shedder’’
in the original study. These results provide strong evidence of
the accuracy of MVS score in correctly identifying infected indi-
viduals independent of their symptoms.
Collectively, our results showed that the MVS was a common
transcriptional signature of a respiratory viral infection, indepen-
dent of the subjects’ symptoms. The MVS was also able to iden-
tify symptomatic subjects prior to symptom onset in an influenza
challenge study. Further, higher MVS scores in other viruses
(adenovirus, enterovirus, and HHV6) in addition to influenza,
RSV, and HRV suggested that the MVS might be more broadly
applicable than respiratory viruses. However, a larger systematic
analysis of diverse viruses would be necessary to identify such a
core signature. Our results also suggest that the MVS might be
able to distinguish other viral infections prior to symptom onset
similar to influenza, though additional challenge studies using
other viruses are needed for validation.1202 Immunity 43, 1199–1211, December 15, 2015 ª2015 Elsevier InIdentification of an Influenza-Specific Response
Signature
A number of studies have previously reported virus- and strain-
specific signatures (Hu et al., 2013; Zaas et al., 2009). There-
fore, we hypothesized that despite a common transcriptional
response to most respiratory viral infections, there might be a
virus-specific transcriptional response. We applied our method
to several influenza infection studies to see whether we could
identify an influenza meta-signature (IMS).
As before, we chose expression profiles from 292 blood sam-
ples in five cohorts from three countries and profiled using two
types ofmicroarrays to represent biological and technical hetero-
geneity. In the discovery cohorts, we used samples from healthy
individuals, patients with bacterial infection, and day 0 (pre-inoc-
ulation) individuals as controls. We used samples with influenza
infection and individuals after inoculation as cases.
We identified 127 genes (FDR < 0.5%) as significantly overex-
pressed (Table S4 and Supplemental Experimental Procedures).
Although our very stringent criterion might have left out some
genes with varying expression in influenza, it allowed for the
identification of a reproducible transcriptional profile that was
found in all five influenza discovery cohorts despite the presence
of significant heterogeneity.
These 127 genes include RIG-1-like receptor (RLR) molecules
(DDX60, DHX58, IFIH1), transcription factors known to be over-
expressed during influenza infection (IRF7, STAT1), interferon-
alpha inducible genes (IFI44, IFI44L, IFI6), transport molecules
(RAB8A), and antiviral molecules such as myxovirus resistance
gene (MX1), 20-50-oligoadenylate synthetases (OAS1, OAS2,
OAS3), guanylate-binding protein 1 (GBP1), and RSAD2. Many
of these genes have been shown to be overexpressed after influ-
enza infection (Ramilo et al., 2007), confirming the validity of our
results. Network analysis of these 127 genes by Ingenuity
Pathway Analysis (IPA) confirmed that 71 of the 127 genes are
part of a network involved in innate virus sensing and initiation
of antiviral response pathways (Figure S2). Thus, our analysis
was able to capture the known biology of the response to influ-
enza by defining a gene subset of the larger, common MVS.
We then applied a leave-one-cohort-out strategy to avoid
the undue influence of a single cohort on the results. We identi-
fied 16 overexpressed genes: CD38, HERC5, HERC6, IFI44L,
IFI6, IFIH1, IFIT1, LGALS3BP, LY6E, MX1, OAS1, OAS2,
PARP12, RTP4, XAF1, and ZBP1, using a very stringent FDR <
0.01%. Of these 16 genes, 5 (IFI44L, IFIT1, OAS1, OAS2, and
XAF1) had significant heterogeneity in effect size (p < 0.025)
andwere removed from further analysis. The remaining 11 genes
were homogeneously overexpressed in patients infected with
influenza across all discovery cohorts (Figures 3A–3K; Table
S5). Network analysis by IPA showed that 10 of these 11 genes
were interconnected, with IRF7 and STAT1 forming a central
axis of transcriptional regulation (Figure 3L). We will now refer
to these 11 genes as the IMS.
The IMS Discriminates Influenza Infection from
Bacterial Infections with High Specificity and Sensitivity
We asked whether the IMS could distinguish between influenza
and bacterial infections, similar to the MVS. Therefore, we
defined the geometric mean of the 11 IMS genes as the IMS
score of a sample. In GSE: GSE40012 (Parnell et al., 2012), thec.
Figure 3. 11-Gene Influenza Meta Signature
(A–K) 11 genes were significantly overexpressed during influenza infection in all discovery cohorts analyzed. The x axes represent standardized mean difference
between influenza and control samples, computed as Hedges’ g, in log2 scale. The size of the blue rectangles is inversely proportional to the SEM in the study.
Whiskers represent the 95% confidence interval. The orange diamonds represent overall, combined mean difference for a given gene. Width of the diamonds
represents the 95% confidence interval of overall mean difference.
(L) Network analysis by Ingenuity Pathway Analysis showed that 10 out of the 11 genes are part of a single regulatory network. Blue nodes in the network represent
IMS genes, and red nodes represent genes that were significantly overexpressed during influenza infection but are not included in the IMS.IMS scores of influenza pneumonia patients were significantly
higher than healthy controls, bacterial pneumonia patients, and
non-infectious SIRS (p = 13 1011; Figure 4A). Importantly, there
was no significant difference between the IMS scores of influ-
enza pneumonia patients and mixed pneumonia patients (indi-
viduals with both influenza and bacterial infections). These
data suggested that even with concurring bacterial infection, in
the same patient the IMS score could still identify influenza infec-
tion.We also showed that using only the samples obtainedwithin
24 hr of hospitalization, the IMS score identified influenza pneu-
monia patients with high specificity and sensitivity (AUC = 0.92;
Figure 4B). These results validate the utility of the IMS as an index
of influenza infection that can distinguish it from bacterial infec-
tion in clinical settings.
Next, we compared the IMS scores from PBMCs of pediatric
patients (age % 18 years) with influenza or bacterial infection
(Staphylococcus aureus, Streptococcus pneumoniae, and
Escherichia coli) in an independent cohort (GSE:GSE6269) (Ram-
ilo et al., 2007). Despite the presence of biological (age, patho-
gens, antibiotics) and technological (three microarray platforms)
confounding factors, the IMS scores of the patients with influenza
infection were significantly higher than those of healthy controls
and patients with bacterial infections (p% 2.83 3 103; Figures
4C, 4E, and4G),with high specificity and sensitivity in distinguish-
ing influenza patients from those with a variety of bacterial infec-
tions (AUC range 0.86–0.97; Figures 4D, 4F, and 4H). The lack
of statistical significance in Figure 4G is an artifact of a very small
sample size (n = 3) in the S. pneumoniae group with an outlier.
Collectively, these results provide strong evidence that the
IMS (1) is able to specifically distinguish influenza infection
from bacterial infections and (2) is not confounded by age or
the array technology used for profiling.
The IMS Can Distinguish Influenza from Other
Respiratory Viruses
The IMS scores of patients with viral infections were not different
from those of virus-negative controls and patients with bacterialImminfections (Figure S3A) or SARS coronavirus (Figure S3B). In fact,
the IMS scores were significantly lower in virus-infected patients
than virus-negative controls (p = 0.003; Figure S3A). In contrast,
the MVS scores were significantly higher in both of these co-
horts. These results suggested that the IMS might be specific
to influenza, because none of the patients in these cohorts
were infected with influenza.
Therefore, we compared the IMS scores of influenza-infected
patients with those of patients with other respiratory viral infec-
tions (RSV and HRV) using three datasets (GSE: GSE34205,
GSE42026, and GSE38900). These datasets profiled whole
blood samples from children (age < 17 years). We note that influ-
enza-infected samples and healthy control samples from
GSE34205 and GSE42026 were used as discovery cohorts for
identification of IMS (Table S1). The IMS scores were signifi-
cantly higher in influenza samples compared to RSV samples
in GSE34205 and GSE38900 (p < 0.0002) and marginally signif-
icant in GSE42026 (p = 0.061; Figures 5A–5C). Influenza samples
also had an IMS score that was significantly higher than that
for HRV samples in GSE38900 (p = 2.33 3 105; Figure 5C).
Notably, in these three datasets, the MVS scores of subjects
with any viral infection were significantly higher than the healthy
controls (p < 13 106) but were similar when compared to each
other (p > 0.05; Figures 5D–5F), with the exception of HRV and
RSV in GSE38900 (p = 0.002; Figure 5F). These data confirmed
that the genes in the IMS were able to accurately discriminate
influenza from other viral infections.
The IMS Score Distinguishes Symptomatic and
Asymptomatic Individuals with High Specificity and
Sensitivity
Similar to the MVS, we further explored the change in the IMS
scores after inoculation in an influenza challenge study (GSE:
GSE52428) and two influenza and bacterial pneumonia cohorts
(GSE: GSE20346 and GSE40012). Both pneumonia cohorts
profiled longitudinal samples that were obtained from patients
within 24 hr of their admission to an intensive care unit. Theunity 43, 1199–1211, December 15, 2015 ª2015 Elsevier Inc. 1203
Figure 4. The IMS Discriminates Influenza Infection from Bacterial Infections with High Specificity and Sensitivity in Multiple Cohorts
ROCs are for distinguishing patients with influenza infection from all other samples in a given cohort.
(A and B) For GSE40012, only samples on the first day of admission are used for violin plot (A) and ROC (B).
(C–H) Violin plots (C, E, G) and ROCs (D, F, H) for samples profiled with three microarray platforms in GSE6269 are displayed individually.
Error bars indicate mean ± SE for a given group of samples. Width of a violin plot indicates density of samples, where each dot represents a sample. See also
Figure S3.challenge study allowed for analysis of the IMS scores during the
initial acute phase of infection, whereas the pneumonia cohorts
allowed for analysis of the IMS scores in patients with an estab-
lished infection as they progress through recovery and resolution
of symptoms.
Similar to theMVS scores, the IMS scores were unchanged for
asymptomatic volunteers inoculated with H3N2 or H1N1 but
increased significantly for symptomatic patients (Figures 6A
and 6B). Furthermore, an increase in the average IMS score of
symptomatic volunteers also preceded symptom onset in both
groups. For example, the IMS scores for all H3N2 symptomatic
volunteers were higher than for asymptomatic volunteers at
69.5 hr after inoculation (AUC = 1; Figure S4A), suggesting that
the IMS score correctly identified symptomatic volunteers prior
to symptom onset. For H1N1 volunteers, who showed symp-
toms later than the H3N2 group (Woods et al., 2013), the IMS
score also began to increase at a later time point as compared
to the H3N2 group, achieving maximum discrimination between
symptomatic and asymptomatic volunteers at 60 hr (AUC = 0.9;
Figure S4B), which was also prior to symptom onset in all H1N1
volunteers. Thus, the kinetics of IMS gene expression might pro-
vide prognostic capability in the clinic for tracking potential
morbidity after a known exposure by identifying susceptible indi-
viduals prior to symptom onset.
However, MVS and IMS behaved differently in the GSE52428
challenge study, where MVS achieved higher discriminatory po-
wer than IMS at the same time point after inoculation (Figures 6C
and 6D). For instance, 36 hr after inoculation, ROC AUCs were
0.94 and 0.65 in the H3N2 cohort for MVS and IMS, respectively.
Similarly for H1N1, 45.5 hr after inoculations, ROC AUCs were1204 Immunity 43, 1199–1211, December 15, 2015 ª2015 Elsevier In0.81 and 0.64 for MVS and IMS, respectively. Furthermore,
IMS scores of symptomatic volunteers remained higher than
those of asymptomatic volunteers at the end of the time course
(Figures 6A and 6B) and is in contrast to MVS scores that began
to decrease toward asymptomatic baseline levels at the same
time point (Figures 2C and 2D). These results suggested that
the MVS, a common transcriptional response to viral infection,
was turned on earlier than the influenza-specific response and
then also returned to baseline earlier than the influenza-specific
response.
In the pneumonia cohorts, our analysis showed that the IMS
score remained unchanged from baseline in healthy controls
and patients with bacterial pneumonia or SIRS (Figures 6E and
6F). In contrast, the IMS scores of the influenza pneumonia pa-
tients were significantly higher than those of bacterial pneumonia
(p = 3.35 3 1013 in GSE40012 and p = 0.0017 in GSE20346) at
the time of admission and progressively decreased over time in
the influenza pneumonia patients (p = 1.3 3 105 in GSE40012
and p = 4.23 3 105 in GSE20346) (Figures 6E and 6F). The
mean IMS score in mixed pneumonia patients, defined as those
with both bacterial and influenza infections, were also signifi-
cantly higher at admission, decreased over time, and were indis-
tinguishable from those of influenza pneumonia patients, sug-
gesting that the IMS score is not confounded by co-infection
with bacterial pathogens.
IMS Score Is Significantly Higher in Vaccine Responders
than Non-responders
The ultimate goal of influenza vaccination is to induce the same
immune response as infection to induce amemory response, butc.
Figure 5. The IMS Scores Distinguish Influenza-Infected Patients from Healthy Controls and Patients with Other Respiratory Viral Infections
but the MVS Scores Do Not
(A–C) In GSE34205 (A) and GSE42026 (B), samples from influenza patients and healthy controls were used for discovery of the IMS, but samples from RSV-
infected patients were not used. None of the samples from GSE38900 (C) were used for discovery of the IMS.
(D–F) All samples from GSE34205 (D) and GSE42026 (E) were used for identification of the MVS. None of the samples from GSE38900 (F) were used for
identification of MVS.
Error bars indicate mean ± SE for a given group of samples. Width of a violin plot indicates density of samples, where each dot represents a sample. See also
Figure S3.without the corresponding pathology. Despite a large number of
influenza infection (Mejias et al., 2013; Parnell et al., 2012; Ramilo
et al., 2007) and vaccination (Franco et al., 2013; Furman et al.,
2013; Nakaya et al., 2011; Tsang et al., 2014) studies, no com-
mon transcriptional signature between influenza and vaccination
has been proposed. Therefore, we explored the change in the
IMS scores after influenza vaccination in three independent co-
horts of 310 individuals.
Tsang et al. (2014) (GSE: GSE47353) divided 63 vaccinated
(Fluvirin, Novartis) healthy individuals into three groups (low,
moderate, and high responders) that were defined as the lowest
20th percentile, 21st to 80th percentile, and above 80th percentile
of microneutralization titers, respectively. The IMS scores
increased significantly for the high (paired t test p = 0.008) and
moderate (paired t test p = 6.36 3 106) responders, but not
for low responders (paired t test p > 0.05) on day 1 after vaccina-
tion compared to day 0 (Figure 7A).
Unlike in Tsang et al. (2014), typically vaccine responders and
non-responders are defined based on 4-fold change in hemag-
glutination-inhibition (HAI) assay titers 28 days after vaccination.
Therefore, we used this definition to categorize responders and
non-responders in two independent vaccination cohorts (GSE:
GSE48018 and GSE48023 from Franco et al., 2013) and
explored whether the IMS scores showed difference between
vaccine responders and non-responders prior to the 28-day
mark. In a cohort of 128 females (GSE48023), the IMS scores
increased significantly on day 3 after vaccination in responders
for H1N1 (paired t test p = 0.002) and H3N2 (paired t test p =
0.015), but not in non-responders (paired t test p > 0.2) (FiguresImm7B and 7C). Similarly, in a cohort of 119 males (GSE48018), the
IMS scores increased significantly in responders for H1N1 and
H3N2 (paired t test p < 2.2 3 1016) on day 1 after vaccination
for both H1N1 and H3N2 (Figures 7D and 7E). However, the
IMS scores also increased significantly in non-responders
(paired t test p < 0.01) for H1N1 and H3N2 in the male cohort,
although the increase in the non-responders after vaccination
was lower than the responders (Figures 7D and 7E). When we
used 4-fold increase in the microneutralization titers on
28 days after vaccination to define responders, the IMS scores
showed similar results for both cohorts (Figure S5). These results
show that the IMS score increases significantly in vaccine re-
sponders and could potentially serve as a marker for successful
vaccination.
The IMSScore Increases in Influenza-Infected Epithelial
Cells
We investigated whether the IMS response could be seen in
epithelial cells, the target cell population for influenza replication.
Indeed, in three independent datasets of 154 samples, the IMS
scores increased significantly in cell lines of epithelial origin
(Calu-3 and A549) after influenza infection (Figure S6).
Next, we compared the IMS scores in primary human bron-
chial epithelial cells (HBECs) after infection with influenza or
treatment with relevant ligands (Shapira et al., 2009). Shapira
et al. (2009) (GSE: GSE19392) used four different strategies to
highlight distinct components of the host response to influenza
infection: (1) infection with wild-type A/PR/8/34 (PR8) influ-
enza virus that can mount a complete replicative cycle; (2)unity 43, 1199–1211, December 15, 2015 ª2015 Elsevier Inc. 1205
Figure 6. IMS Score Is a Prognostic Marker of Influenza Infection
(A and B) IMS scores in symptomatic and asymptomatic subjects inoculated with influenza A (H3N2 in A; H1N1 in B). Smoothed lines indicate loess curves for
symptomatic and asymptomatic subjects. Gray bars indicate 95% confidence interval.
(C and D) Comparison of MVS and IMS scores in the same subjects inoculated with H3N2 (C) or H1N1 (D).
(E and F) Change in IMS scores in healthy controls and patients with non-infectious systemic inflammatory response, influenza pneumonia, bacterial pneumonia,
or both (influenza and bacterial pneumonia) during their stay in the hospital.
See also Figure S4.transfection with viral RNA (vRNA) isolated from influenza parti-
cles, which does not result in the production of viral proteins or
particles; (3) treatment with interferon beta (IFN-b) to identify re-
sponses mediated through type 1 interferons (IFNs); and (4)
infection with a PR8 mutant virus lacking the NS1 gene
(DNS1), which normally inhibits vRNA- or IFN-b-induced path-
ways in host cells.1206 Immunity 43, 1199–1211, December 15, 2015 ª2015 Elsevier InIMS scores increased significantly for all strategies (Figure S7),
where the kinetics and magnitude of the increase in the IMS
score reflected the hierarchy of influenza virus detection in the
epithelial cells and host response. For example, at 18 hr after
infection, IMS scores were the lowest after infection with wild-
type PR8 influenza virus. However, the magnitude of the change
in the average IMS score at 18 hr after infection was higher forc.
Figure 7. IMS Score Increases Significantly in Vaccine Responders
(A) Change in IMS scores on day 1 after vaccination for high (p = 0.008), moderate (p = 6.36 3 106), and low (p > 0.05) responders defined based on micro-
neutralization titers.
(B and C) Change in IMS scores for vaccine responders and non-responders, defined based on HAI titers, in a female cohort after influenza vaccination (H1N1 in
B; H3N2 in C).
(D and E) Change in IMS scores for vaccine responders and non-responders, defined based on HAI titers, in a male cohort after influenza vaccination (H1N1 in D;
H3N2 in E).
See also Figure S5.cells exposed to influenza viral RNA, infected with PR8 influenza
virus lacking NS1 protein, or treated with IFN-b and is probably
due to the absence of the NS1 protein that inhibits vRNA- or
IFN-b-induced pathways in each of these conditions.
Furthermore, the increase in the IMS score was fastest in cells
treated with IFN-b (1.5 hr), slowest for infection with wild-type
PR8 influenza virus with or without NS1 protein (6 hr), and inter-
mediate for transfection with only viral RNA (4 hr). Taken
together, these differences in the timing of when the averageImmIMS score begins to rise suggests that the IMS consists of
host response genes that are directly or indirectly targeted by
the influenza virus to suppress the host response, evade detec-
tion, and dampen the effects of IFN-b.
DISCUSSION
The goal of this studywas to integrate gene expression data from
multiple heterogeneous sources to define both a conserved hostunity 43, 1199–1211, December 15, 2015 ª2015 Elsevier Inc. 1207
response to respiratory viral infection and one specific to influ-
enza. These dual goals could be useful in multiple settings,
such as determining (1) the likely prognosis in a viral infection,
(2) the diagnosis of a specific viral infection, (3) identifying vac-
cine responders, and (4) uncovering new biological pathways
and possible drug targets for further study.
Using our previously described multi-cohort analysis frame-
work, we analyzed 26 independent cohorts from 18 datasets
consisting of 2,939 samples that were collected in 7 countries
and represented infections from 7 viruses and 4 bacteria in
whole blood, PBMCs, and epithelial cells to identify the MVS
and IMS that are robustly and consistently differentially ex-
pressed across age, gender, clinical time course, and illness
severity. Our results showed that the MVS is able to (1) distin-
guish virus-infected patients from those with bacterial infections
or healthy controls with high accuracy and (2) identify influenza-
infected subjects at risk for being ill before onset of clinical
symptoms. Although the clinical utility of the MVS might be
limited due to the large number of genes in the signature, it pro-
vides a potential starting point for simpler diagnostic gene sets.
Importantly, it has identified novel pathways to better under-
stand viral host response and identify targets for novel anti-viral
therapies. We also showed that the IMS (1) is specific to influ-
enza infection, (2) is able to distinguish influenza infection
from bacterial infections, (3) is predictive of clinical illness in
challenge studies, (4) is prognostic in influenza pneumonia pa-
tients, (5) is correlated with gene expression changes in sub-
jects responding to influenza vaccination, and (6) showed
different dynamics in males and females after influenza
vaccination.
Although several groups have proposed influenza infection-
specific gene sets, there is little overlap among them. For
instance, although the total number of genes reported by these
studies ranged from 25 to 615, none of the IMS genes were re-
ported by all studies. For example, the most reported gene,
MX1, was reported as being overexpressed by only seven data-
sets, whereas CD38was reported as overexpressed by only one
dataset. These observed discrepancies in the reported results of
influenza infection across multiple studies also underscore the
importance and advantage of using our rigorous integrated
multi-cohort analysis approach. It enables the researchers to
leverage the large amounts of publicly available datasets and
the biological and technological heterogeneity present among
them to create ‘‘Big Data’’ from multiple ‘‘Small Data’’ that are
better representative of the heterogeneity observed in the real-
world population. This approach has been previously found
to be effective at uncovering genes with consistent expression
profiles that are mechanistic, diagnostic, and therapeutic
(Chen et al., 2014; Khatri et al., 2013; Li et al., 2015; Mazur
et al., 2014; Sweeney et al., 2015).
Identification and validation of these robust and reproducible
signatures across multiple independent cohorts could in turn
enable further systematic global analyses. For instance, none
of the existing studies of influenza infection and vaccination
have explored how their proposed signatures relate infection
and vaccination to each other (Furman et al., 2014; Hu et al.,
2013; Li et al., 2014; Nakaya et al., 2011; Parnell et al., 2011,
2012; Ramilo et al., 2007; Tsang et al., 2014; Woods et al.,
2013). In contrast, we explored the IMS in three influenza vacci-1208 Immunity 43, 1199–1211, December 15, 2015 ª2015 Elsevier Innation studies to show that the same signature also correlates
with influenza vaccine response, thereby bridging the gap be-
tween influenza infection and vaccination because the IMS is
diagnostic and prognostic in influenza-infected patients and cor-
relates with vaccine response.
Compelling clinical data have shown that men and women
differ in their innate, humoral, and cell-mediated response to viral
vaccines (Klein et al., 2010). For example, testosterone can have
immunosuppressive role in response to influenza vaccination
(Furman et al., 2014). In line with this, the IMS scores changed
significantly in responders on day 1 for males and on day 3 for
females after vaccination. These results suggest that the effect
of sex differences on immune response might be more nuanced
in that males respond sooner to vaccination compared to fe-
males and that sex differences might also have an effect on
the dynamics of an immune response, not just its magnitude.
These results further suggest that future vaccination studies
should be designed to sample subjects more frequently in the
first 3 days after vaccination to further understand sex differ-
ences in immune response after vaccination.
Jenner and Young (2005) previously carried out an analysis of
785 samples in 32 studies. However, contrary to our integrated
multi-cohort analysis, which focused on identifying a robust
signature of viral infection, their analysis focused on identifying
a common transcriptional response to pathogenic infections ir-
respective of source (bacterial or viral). Furthermore, their anal-
ysis relied on a clustering of gene expression patterns across all
studies to identify a ‘‘common host response’’ of 511 genes,
where these genes were not ubiquitously expressed across all
datasets. Instead, we employed an established statistical
framework to account for the variability of gene expression,
array types, and the number of samples within each study. In
addition, all samples used in our analysis for the identification
of MVS and IMS were peripheral blood samples, whereas Jen-
ner and Young (2005) used samples from various sources
including cell lines, sorted immune cells, and other tissues (liver,
skin, astrocytes, fibroblasts, etc.). Because of these important
differences in study design, many genes identified by Jenner
and Young (2005) as those mediating inflammation were not
significantly differentially expressed in our analysis, because
they are probably overexpressed during both bacterial and viral
infections compared to uninfected individuals. However, a num-
ber of the IFN-inducible genes they identified were also overex-
pressed in our analysis, suggesting that although these genes
are overexpressed during bacterial and viral infections, they
have greater changes in their expression after influenza infec-
tion than bacterial infections.
Many type-1-interferon-stimulated genes (ISGs) have been
reported in the literature. However, depending on the cell
type, IFN dose, and time of treatment, the number of ISGs
can vary from 50 to 1,000 (Schoggins and Rice, 2011). Thus,
it has remained unclear which of these genes were most
relevant to influenza infection. Herein we identified a concise
influenza response signature with many ISGs. Indeed, IFN-b
treatment of HBECs suggests that some or all of the genes in
the IMS are stimulated by IFN. This finding indicates that
whereas ISGs are a common element among signatures, a
concise and specific gene subset features most importantly in
response to influenza.c.
Although the IMS was identified using whole blood or PBMC
samples, most of the IMS genes were also overexpressed after
influenza infection in primary human bronchial epithelial cells
and lung adenocarcinoma cell lines A549 and Calu-3. These
results provide further evidence of the conservation of the
response to influenza infection and identify a correlation be-
tween the systemic immune response in blood and epithelium
at the onset of infection as has been observed before (Ioannidis
et al., 2012). However, not all IMS genes were overexpressed in
these in vitro studies. For example, as expected, CD38 was not
differentially expressed, since its expression is specific to lym-
phocytes (Moreno-Garcı´a et al., 2005; Sandoval-Montes and
Santos-Argumedo, 2005). These results suggest that the IMS
response to influenza infection is present in both circulating
blood and in separate tissue types.
This paper has some limitations. First, the MVS gene set might
include too many genes to allow for a simple clinical test; further
optimization might be needed before reduction to practice. Sec-
ond, the IMS signature was specific to influenza against the other
viral infections for which data were available, but there are other
clinical infections similar to influenza infection (i.e., parainfluenza
infection) that would need further testing. Finally, prospective
testing will be needed for both gene sets.
The commonality of the MVS across multiple viral infections
and specificity of the IMS for influenza infection suggest a num-
ber of potential applications. First, the MVS could serve as a
starting point to identify broad host factor targets for developing
broad-spectrum anti-viral drugs. Most of the existing anti-viral
drugs are based on the one-drug-one-bug philosophy, which
is inefficient and ineffective because viruses often mutate to
develop drug resistance and novel viral strains can emerge
from animal carriers. Instead, developing anti-viral drugs that
target host factors involved in multiple respiratory viral infections
could provide protection against a broader group of viruses and
be more effective against novel strains. Second, the IMS score
can be used clinically to distinguish influenza infections, regard-
less of whether there is concurrent bacterial pneumonia, which
could help clinicians to determine whether to initiate antiviral
treatments in patients with potential co-infections. Third, the
IMS score can be used as a more objective measure of a vacci-
nation response. Our results in influenza-vaccinated individuals
show that the IMS score increases significantly in responders
but remains unchanged in non-responders.
Finally, the specificity of IMS to influenza compared to other
respiratory viruses enables identification of a virus-specific im-
mune metric that can be applied to both vaccination and natural
infection studies, and might be a starting place for studies of dif-
ferential biology of influenza infection. In general, the ability to
define metrics for the immune system, such as we have done
here, goes beyond the concept of biomarkers and provides a
means to measure and understand functional and, potentially,
mechanistic pathophysiological relationships for other disease-
specific clinical cohorts.EXPERIMENTAL PROCEDURES
Data Collection and Pre-processing
Our entire analysis was performed with publicly available data. We down-
loaded 18 microarray gene expression datasets from the NCBI GEOImmcomprising 2,939 samples derived from whole blood, PBMCs, epithelial cells,
or cell lines (Table S1). The samples in these datasets represented different
biological conditions including viral infections (influenza, RSV, HRV, SARS,
adenovirus, enterovirus, HHV6), bacterial infections (E. coli, S. aureus,
S. pneumonie, Salmonella), non-pathogenic systematic inflammatory
response, and healthy controls. We incorporated technical heterogeneity in
our analysis by choosing datasets that were profiled using microarrays from
different manufacturers. All datasets, except one (GSE: GSE19392), are whole
blood or PBMC samples obtained from patients with or without a viral infection
over wide range of ages (from fewer than 2 months to more than 60 years).
Furthermore, the samples were independently collected and profiled at 14
centers in 7 countries. Supplemental Experimental Procedures provide brief
description of each of these datasets.
For all datasets, we verified that the expression was normalized and log2-
transformed. For each study, we used the sample phenotypes as defined by
the primary publication of a source study. Microarray probes in each dataset
were mapped to Entrez Gene identifiers (IDs) to facilitate integrated analysis. If
a probe matched more than one gene, the expression data for that probe were
expanded to add one record for each mapped gene (Ramasamy et al., 2008).
Integrating Discovery Cohorts by Meta-analysis
We applied two meta-analysis methods as described in our previous publica-
tions (Figure S1; Tables S1 and S2): (1) combining effect sizes and (2)
combining p values (Chen et al., 2014; Khatri et al., 2013; Sweeney et al.,
2015). We estimated the effect size for each gene in each dataset as Hedges’
adjusted g. If multiple probes mapped to a gene, the effect size for each gene
was summarized via the fixed effect inverse-variance model. The study-spe-
cific effect sizes for each gene were then combined into a single meta ef-
fect-size using a linear combination of study-specific effect sizes, fi, where
each study-specific effect size was weighted by inverse of the variance in
the corresponding study. After computing meta effect-size, p values were cor-
rected for multiple hypotheses testing via Benjamini-Hochberg false discovery
rate (FDR) correction (Benjamini and Hochberg, 1995), and significant genes
were identified via Z-statistic.
We used Fisher’s sum of logs method (Fisher, 1934) for meta-analysis by
combining p values. For each gene, we summed the logarithm of the one-
sided hypothesis testing p values across k studies and compared the result
to a c2-distribution with 2k degrees of freedom.
In order to avoid influence of a dataset with a large sample size on the re-
sults, we removed one dataset at a time and applied both meta-analysis
methods at each iteration.We did not filter for heterogeneity between datasets
when identifying MVS because different viruses can induce various genes at
different levels. However, we ensured that there was no significant heteroge-
neity (p > 0.05) in effect size across all datasets for the IMS.
Meta Virus Signature and Influenza Meta-Signature Score
We defined the MVS score of a sample as the geometric mean of the normal-
ized, log2-transformed expression of the 161 overexpressed genes minus that
of the 235 underexpressed genes. We defined the IMS score of a sample as
the geometric mean of the normalized log2-transformed expression of the
11 overexpressed genes. We scaled and centered the MVS or IMS scores of
all samples in a given dataset (mean = 0, standard deviation = 1) to enable
comparisons between datasets. We used the Wilcoxon-Mann-Whitney
(Wilcoxon, 1945) or ANOVA to test whether there was a statistically significant
difference between the MVS or IMS scores of two groups.
If a dataset contained negative values, computing a geometric mean is not
possible. In these datasets, we usedmean of the normalized log2-transformed
expression values to compute the MVS and IMS scores.
Pathway Analysis
We performed functional pathway analysis via iPathwayGuide (Draghici et al.,
2007; Khatri et al., 2008; Tarca et al., 2009). Meta-effect size across all viral in-
fections was used as fold change in iPathwayGuide to identify significant path-
ways.We used FDR% 10%as a threshold for identifying significant pathways.
We performed network analysis of influenza-specific genes by IPA with an op-
tion to include only ‘‘direct relationship’’ to avoid spurious connections caused
by ‘‘indirect relations.’’ Direct relationships in IPA result from publications cit-
ing experimental evidence for an interaction.unity 43, 1199–1211, December 15, 2015 ª2015 Elsevier Inc. 1209
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